These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34815524)

  • 1. PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer.
    Wen YC; Liu CL; Yeh HL; Chen WH; Jiang KC; Tram VTN; Hsiao M; Huang J; Chen WY; Liu YN
    Br J Cancer; 2022 Mar; 126(5):778-790. PubMed ID: 34815524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46.
    Liu YN; Niu S; Chen WY; Zhang Q; Tao Y; Chen WH; Jiang KC; Chen X; Shi H; Liu A; Li J; Li Y; Lee YC; Zhang X; Huang J
    Clin Cancer Res; 2019 Jul; 25(13):4128-4140. PubMed ID: 30962287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
    Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27
    Tuo L; Xiang J; Pan X; Hu J; Tang H; Liang L; Xia J; Hu Y; Zhang W; Huang A; Wang K; Tang N
    J Exp Clin Cancer Res; 2019 Feb; 38(1):50. PubMed ID: 30717766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Fararjeh AS; Liu YN
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of PCK1 Gene Antagonizes Hepatocellular Carcinoma Through the Activation of Gluconeogenesis and Suppression of Glycolysis Pathways.
    Tang Y; Zhang Y; Wang C; Sun Z; Li L; Cheng S; Zhou W
    Cell Physiol Biochem; 2018; 47(1):344-355. PubMed ID: 29768256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer.
    Lin SR; Wen YC; Yeh HL; Jiang KC; Chen WH; Mokgautsi N; Huang J; Chen WY; Liu YN
    Oncogene; 2020 Oct; 39(44):6757-6775. PubMed ID: 32963351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting SOX4/PCK2 signaling suppresses neuroendocrine trans-differentiation of castration-resistant prostate cancer.
    Jing N; Tao Z; Du X; Wen Z; Gao WQ; Dong B; Fang YX
    Biol Direct; 2024 Jul; 19(1):56. PubMed ID: 39014441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rev-erbα activation down-regulates hepatic Pck1 enzyme to lower plasma glucose in mice.
    Yuan X; Dong D; Li Z; Wu B
    Pharmacol Res; 2019 Mar; 141():310-318. PubMed ID: 30639375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
    Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
    Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunosuppressive role of BDNF in therapy-induced neuroendocrine prostate cancer.
    Liu YN; Chen WY; Liu MK; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Wang WH; Abou-Kheir W; Wen YC
    Mol Oncol; 2024 Jun; 18(6):1665-1686. PubMed ID: 38381121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
    Puca L; Gavyert K; Sailer V; Conteduca V; Dardenne E; Sigouros M; Isse K; Kearney M; Vosoughi A; Fernandez L; Pan H; Motanagh S; Hess J; Donoghue AJ; Sboner A; Wang Y; Dittamore R; Rickman D; Nanus DM; Tagawa ST; Elemento O; Mosquera JM; Saunders L; Beltran H
    Sci Transl Med; 2019 Mar; 11(484):. PubMed ID: 30894499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.
    Chen WY; Tsai YC; Siu MK; Yeh HL; Chen CL; Yin JJ; Huang J; Liu YN
    Oncogene; 2017 Nov; 36(45):6213-6224. PubMed ID: 28692046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
    Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
    Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T3 and glucose increase expression of phosphoenolpyruvate carboxykinase (PCK1) leading to increased β-cell proliferation.
    Katz LS; Argmann C; Lambertini L; Scott DK
    Mol Metab; 2022 Dec; 66():101646. PubMed ID: 36455788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oncoprotein HBXIP suppresses gluconeogenesis through modulating PCK1 to enhance the growth of hepatoma cells.
    Shi H; Fang R; Li Y; Li L; Zhang W; Wang H; Chen F; Zhang S; Zhang X; Ye L
    Cancer Lett; 2016 Nov; 382(2):147-156. PubMed ID: 27609066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-200a suppresses prostate cancer progression through BRD4/AR signaling pathway.
    Guan H; You Z; Wang C; Fang F; Peng R; Mao L; Xu B; Chen M
    Cancer Med; 2019 Apr; 8(4):1474-1485. PubMed ID: 30784214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.